Announced details
Refractory vascular anomalies (venous malformations, lymphatic malformations, and Klippel–Trenaunay syndrome)
Primary endpoint response rate: 30.6% (11/36 patients), with p<0.001 versus the prespecified null-hypothesis response rate of 6.7%. Changes in pain scores ranged from −10.7±13.34 to −4.4±12.59 mm at 4 to 52 weeks after dosing in the population with baseline pain.
36 patients in the domestic Phase 3 confirmatory study (dosed for at least 24 weeks and up to 52 weeks)
The venue at which KAKEN PHARMACEUTICAL CO., LTD. presented the results of its domestic Phase 3 confirmatory study.
An academic meeting held in Morioka, Iwate Prefecture, on 16–17 July 2026.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
22nd Annual Meeting of the Japanese Society for Hemangioma and Vascular Malformations; Information website of the Research Group for Pharmacotherapy of Refractory Hemangiomas and Vascular Malformations
| Item | Details |
|---|---|
| Names of Products / Services Covered | KP-001 (generic name: ceraverisib phosphate hydrate) |
| Counterparty | 22nd Annual Meeting of the Japanese Society for Hemangioma and Vascular Malformations |
| Counterparty overview | An academic meeting held in Morioka, Iwate Prefecture, on 16–17 July 2026. |
| Relationship with the Company | The venue at which KAKEN PHARMACEUTICAL CO., LTD. presented the results of its domestic Phase 3 confirmatory study. |
| Applicable area | Refractory vascular anomalies (venous malformations, lymphatic malformations, and Klippel–Trenaunay syndrome) |
| Quantitative Effects | Primary endpoint response rate: 30.6% (11/36 patients), with p<0.001 versus the prespecified null-hypothesis response rate of 6.7%. Changes in pain scores ranged from −10.7±13.34 to −4.4±12.59 mm at 4 to 52 weeks after dosing in the population with baseline pain. |
| Usage history | 36 patients in the domestic Phase 3 confirmatory study (dosed for at least 24 weeks and up to 52 weeks) |
| Source | 22nd Annual Meeting of the Japanese Society for Hemangioma and Vascular Malformations; Information website of the Research Group for Pharmacotherapy of Refractory Hemangiomas and Vascular Malformations |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The results of the domestic Phase 3 confirmatory study were presented at the 22nd Annual Meeting of the Japanese Society for Hemangioma and Vascular Malformations.